Journal of Vaccines & Vaccination

M2SR: A robust flu vaccine with long-lasting, cross-protective immunity

4^th International Conference on Vaccines & Vaccination

September 24-26, 2014 Valencia Convention Centre, Spain

Pamuk Bilsel

Scientific Tracks Abstracts: J Vaccines Vaccin

Abstract:

I nfluenza (flu) virus causes a respiratory disease resulting in over 200, 000 hospitalizations and ~36, 000 deaths per year in the US Flu vaccines have remained virtually unchanged for decades. Despite the annual update of the three hemagglutinin (HA) vaccine antigens to match the circulating influenza strain, current vaccine efficacy is estimated to be ~60% across the population as a whole and much less for the elderly. Flu vaccine protection is sub-optimal and substantially lower than for most routinely recommended vaccines. The low efficacy rates are due primarily to the relatively poor immune response provided by both inactivated and live vaccines. There is an urgent need for highly protective flu vaccines that provide broad-spectrum immunity across all segments of the population. FluGen has developed a new vaccine, M2SR (Single Replication), which exploits the best features of both inactivated and live attenuated influenza vaccines. Like the inactivated vaccine, it elicits a strong humoral response against the major neutralizing antigen, the HA. Similar to the live attenuated influenza vaccine, it is administered intranasally to mimic a natural infection and induce broad-spectrum immunity including mucosal and cell- mediated responses. The novelty of M2SR is that the vaccine virus presents multiple antigen targets to the immune system like a wild-type virus and activates the immune system without production of progeny virus. We have shown that the M2SR vaccine provides broad-spectrum, long-lasting cross-protection against multiple influenza subtypes including H5N1 in mice and ferrets.

Biography :

Pamuk Bilsel, PhD is Chief Scientific Officer at FluGen, Inc. Prior joining FluGen as Head of Research and Development she was at Pharmexa-Epimmune developing DNA vaccines based on cell mediated immunity against influenza and malaria. At Pentamer Pharmaceuticals, she developed subunit vaccines against respiratory syncytial virus using virus-like particle technology. Preceding that, she worked at Aviron generating live attenuated influenza vaccine strains in addition to studies with the cold-adapted influenza vaccine which was eventually launched as MedImmune?s FluMist?. Her Post-doctoral training was at St. Jude Children?s Research Hospital with Dr. Yoshihiro Kawaoka.